These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 511016)

  • 1. Heparin-antithrombin III binding. In vitro and in vivo studies.
    Chan V; Chan TK
    Haemostasis; 1979; 8(6):373-89. PubMed ID: 511016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis.
    Barrowcliffe TW
    Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex.
    Andersson LO; Engman L; Henningsson E
    J Immunol Methods; 1977; 14(3-4):271-81. PubMed ID: 557071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on antithrombin III in normal plasma and serum.
    Sas G; Pepper DS; Cash JD
    Br J Haematol; 1975 Jul; 30(3):265-72. PubMed ID: 1201212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced decrease in circulating antithrombin-III.
    Marciniak E; Gockerman JP
    Lancet; 1977 Sep; 2(8038):581-4. PubMed ID: 71399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new familial variant of antithrombin III: 'antithrombin III Paris'.
    Wolf M; Boyer C; Lavergne JM; Larrieu MJ
    Br J Haematol; 1982 Jun; 51(2):285-95. PubMed ID: 7082587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin.
    Clemmensen I
    Thromb Haemost; 1978 Jun; 39(3):616-23. PubMed ID: 705690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the mechanism of the rate-enhancing effect of heparin on the thrombin-antithrombin III reaction.
    Holmer E; Söderström G; Andersson LO
    Eur J Biochem; 1979 Jan; 93(1):1-5. PubMed ID: 436823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells.
    Chan TK; Chan V
    Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of elimination of antithrombin III concentrate in heparinized patients.
    Marciniak E; Gockerman JP
    Br J Haematol; 1981 Aug; 48(4):617-25. PubMed ID: 7272219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.
    Collen D; Schetz J; de Cock F; Holmer E; Verstraete M
    Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies against antithrombin III. Identification of their epitopes and effects on antithrombin III activities.
    Knoller S; Savion N
    Eur J Biochem; 1989 Mar; 180(2):319-26. PubMed ID: 2466666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of low-dose heparin prophylaxis of venous thrombosis considering plasma heparin and anti-thrombin III concentration.
    Tilsner V; Müller U; Reuter H; Raedler A
    Thromb Res; 1980 Feb 1-15; 17(3-4):519-25. PubMed ID: 7368173
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombin III in 86 patients with venous thrombosis (author's transl)].
    Juillet Y; Aiach M; Fiessinger JN; Leclerc M; Housset E
    Sem Hop; 1978 Nov 8-15; 54(37-40):1126-9. PubMed ID: 217091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of the thrombin clotting time and activated partial thromboplastin time to low level of antithrombin III during heparin therapy.
    Delorme MA; Inwood MJ; O'Keefe B
    Clin Lab Haematol; 1990; 12(4):433-6. PubMed ID: 2081384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the heterogeneity of antithrombin III concentrates.
    Barrowcliffe TW; Eggleton CA; Mahmoud M
    Br J Haematol; 1983 Sep; 55(1):37-46. PubMed ID: 6882687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.